Tumour markers in colorectal cancer

Area of Science:

• Oncology
• Clinical Chemistry

Background:

• Colorectal cancer management relies on accurate diagnostic and monitoring biomarkers.
• Carcinoembryonic antigen (CEA) is a widely used tumor marker for colorectal cancer.

Purpose of the Study:

• To evaluate the diagnostic and monitoring utility of Carcinoembryonic antigen (CEA) in colorectal cancer.
• To assess the role of other monoclonal antibodies (CA 19-9, CA 50, CA 125) in conjunction with CEA.

Main Methods:

• Analysis of Carcinoembryonic antigen (CEA) sensitivity and specificity across different Dukes' stages (A-D).
• Evaluation of CEA's performance in detecting distant metastases and local recurrence postoperatively.
• Assessment of alternative markers (CA 19-9, CA 50, CA 125) when CEA results are inconclusive.

Main Results:

• CEA sensitivity for colorectal cancer ranges from 30% (Dukes' A) to 85% (Dukes' D).
• CEA demonstrates 85% sensitivity and specificity for distant metastases and 40% sensitivity with 80% specificity for local recurrence.
• CA 19-9 and CA 50 may provide additional information, particularly when CEA is negative postoperatively.

Conclusions:

• Carcinoembryonic antigen (CEA) is a valuable tool for colorectal cancer diagnosis and postoperative monitoring, especially for detecting metastases.
• CEA's effectiveness varies by disease stage, with lower sensitivity in early stages.
• Alternative markers like CA 19-9 and CA 50 can supplement CEA monitoring in specific clinical scenarios.